Drug Profile
SB 01
Alternative Names: BPR 0L075; DBPR104; SB01; SCB 01ALatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator National Health Research Institutes
- Developer SynCore Biotechnology
- Class Antineoplastics; Indoles; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Head and neck cancer
- No development reported Solid tumours
Most Recent Events
- 08 Sep 2021 Phase II development for Head and neck cancer is ongoing in Taiwan (Syncore Biotechnology pipeline, September 2021)
- 01 Sep 2021 SB 01 is available for licensing in World as of 01 Sep 2021. https://www.syncorebio.com/en/partnering/ (SynCore Biotechnology pipeline, September 2021)
- 17 Nov 2020 SynCore Biotechnology completes a long-term compassionate use phase I trial for Solid tumours in USA(NCT01151930)